Louisiana Research Center | Shreveport, LA

Research site
1800 East 70th Street, Shreveport, Louisiana, United States of America
Site insights

Top conditions

Crohn Disease (23 trials)

Ulcerative Colitis (20 trials)

Colitis (20 trials)

Non-alcoholic Fatty Liver Disease (19 trials)

Fatty Liver (19 trials)

Top treatments

Obeticholic Acid

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


16 of 95
Status: Active
Trial type: Interventional
Funder type: Industry

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (ELFIDENCE)

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC).Participants will also have inadequate response or intolerance t...

Primary Biliary Cholangitis (PBC)
Other: Matched 80 mg placebo
Drug: Elafibranor

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Cirrhosis, Liver
Drug: Resmetirom
Drug: Placebo

CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. Th...

Active, not recruiting
Crohn's Disease
Other: Blood Draw
Other: CDPATH™

The main aim of the study is to check for long-term side effects of Vedolizumab Subcutaneous (also known as Vedolizumab SC) in people with ulcerative...

Active, not recruiting
Colitis, Ulcerative
Crohn's Disease
Drug: Vedolizumab SC

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of gus...

Active, not recruiting
Crohn's Disease
Drug: Guselkumab Dose 3
Drug: Ustekinumab
Locations recently updated

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the...

Crohn's Disease
Drug: Placebo for risankizumab
Drug: Risankizumab SC

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who respond...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: risankizumab
Drug: placebo for risankizumab

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

This study is open to adults who are at least 18 years old and havepresumed or confirmed NASH together with overweight or obesity anda body mass inde...

Non-Alcoholic SteatoHepatitis (NASH)
Drug: Placebo
Drug: Survodutide

The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy...

Active, not recruiting
Ulcerative Colitis
Drug: Filgotinib
Drug: Placebo

This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non al...

Active, not recruiting
Non-alcoholic Steatohepatitis
Drug: NNC0174 0833 10 mg/mL
Drug: NNC0194 0499 50 mg/mL

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabe...

Non-alcoholic Steatohepatitis
Drug: Placebo
Drug: Semaglutide

This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (stea...

Non Alcoholic Steatohepatitis (NASH)
Drug: AXA1125
Drug: Placebo

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankiz...

Active, not recruiting
Crohn's Disease (CD)
Drug: Ustekinumab
Drug: Risankizumab

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: Cilofexor (CILO)/Firsocostat (FIR)

Trial sponsors

Shire logo

Shire (11 trials)

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems